130 related articles for article (PubMed ID: 15668288)
1. Clinical and pharmacokinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinoma.
Katsaros D; Oletti MV; Rigault de la Longrais IA; Ferrero A; Celano A; Fracchioli S; Donadio M; Passera R; Cattel L; Bumma C
Ann Oncol; 2005 Feb; 16(2):300-6. PubMed ID: 15668288
[TBL] [Abstract][Full Text] [Related]
2. Pegylated liposomal doxorubicin and vinorelbine in recurrent ovarian carcinoma: a pharmacokinetic study on alternate administration sequences.
Cattel L; Passera R; Katsaros D; Medail M; Milla P; Ferrero AM
Anticancer Res; 2006; 26(1B):745-50. PubMed ID: 16739347
[TBL] [Abstract][Full Text] [Related]
3. Pegylated liposomal doxorubicin with vinorelbine in metastatic breast carcinoma. A phase I-II clinical investigation.
Gebbia V; Mauceri G; Fallica G; Borsellino N; Tirrito ML; Testa A; Varvara F; Colombo A; Ferrera P
Oncology; 2002; 63(1):23-30. PubMed ID: 12187067
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer.
Aravantinos G; Bafaloukos D; Fountzilas G; Christodoulou C; Papadimitriou C; Pavlidis N; Kalofonos HP; Gogas H; Kosmidis P; Dimopoulos MA
Ann Oncol; 2003 Jul; 14(7):1094-9. PubMed ID: 12853352
[TBL] [Abstract][Full Text] [Related]
5. Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: A phase I-II clinical trial.
Campisi C; Fabi A; Papaldo P; Tomao S; Massidda B; Zappala A; Ionta MT; Cognetti F
Cancer Chemother Pharmacol; 1999; 44 Suppl():S1-4. PubMed ID: 10602901
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients. May a new treatment schedule improve toxicity profile?
Lorusso D; Naldini A; Testa A; D'Agostino G; Scambia G; Ferrandina G
Oncology; 2004; 67(3-4):243-9. PubMed ID: 15557785
[TBL] [Abstract][Full Text] [Related]
7. An escalating dose finding study of liposomal doxorubicin and vinorelbine for the treatment of refractory or resistant epithelial ovarian cancer.
Tambaro R; Greggi S; Iaffaioli RV; Rossi A; Pisano C; Manzione L; Ferrari E; Di Maio M; Iodice F; Casella G; Laurelli G; Pignata S
Ann Oncol; 2003 Sep; 14(9):1406-11. PubMed ID: 12954580
[TBL] [Abstract][Full Text] [Related]
8. [Combined pegylated liposomal doxorubicin and carboplatin in the treatment of recurrent epithelial ovarian cancer].
Zheng H; Gao YN; Jiang GQ; Gao M; Wang W; Yan X
Zhonghua Fu Chan Ke Za Zhi; 2008 Nov; 43(11):839-42. PubMed ID: 19087568
[TBL] [Abstract][Full Text] [Related]
9. Salvage chemotherapy with docetaxel and pegylated liposomal doxorubicin in pretreated patients with platinum- and taxane-sensitive ovarian cancer: a multicenter phase II trial of the Hellenic Oncology Research Group (HORG).
Koinis F; Polyzos A; Christopoulou A; Zafeiriou Z; Emmanouilidis C; Papadimitraki E; Kalykaki A; Kalbakis K; Samonis G; Georgoulias V
Cancer Chemother Pharmacol; 2014 Apr; 73(4):819-25. PubMed ID: 24531559
[TBL] [Abstract][Full Text] [Related]
10. Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: a phase Ib study.
Crespo G; Sierra M; Losa R; Berros JP; Villanueva N; Fra J; Fonseca PJ; Luque M; Fernández Y; Blay P; Sanmamed M; Muriel C; Esteban E; Lacave AJ
Int J Gynecol Cancer; 2011 Apr; 21(3):478-85. PubMed ID: 21436695
[TBL] [Abstract][Full Text] [Related]
11. A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum-Sensitive Ovarian Cancer.
Pignata S; Scambia G; Villanucci A; Naglieri E; Ibarbia MA; Brusa F; Bourgeois H; Sorio R; Casado A; Reichert D; Dopchie C; De Rivas B; de Sande LM
Oncologist; 2021 Apr; 26(4):e658-e668. PubMed ID: 33289956
[TBL] [Abstract][Full Text] [Related]
12. Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (HeCOG).
Janinis J; Stathopoulos GP; Nikolaidis P; Kalofonos HP; Kalogera-Fountzila A; Samantas E; Aravantinos G; Anagnostopoulos A; Tolis C; Makatsoris T; Rigatos SK; Bafaloukos D; Dimopoulos MA; Daniilidis J; Fountzilas G
Anticancer Drugs; 2004 Jun; 15(5):479-87. PubMed ID: 15166622
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study.
Power P; Stuart G; Oza A; Provencher D; Bentley JR; Miller WH; Pouliot JF
Gynecol Oncol; 2009 Sep; 114(3):410-4. PubMed ID: 19520420
[TBL] [Abstract][Full Text] [Related]
14. Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study.
Jehn CF; Hemmati P; Lehenbauer-Dehm S; Kümmel S; Flath B; Schmid P
Clin Breast Cancer; 2016 Dec; 16(6):514-519. PubMed ID: 27395417
[TBL] [Abstract][Full Text] [Related]
15. A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study.
Vici P; Colucci G; Giotta F; Sergi D; Filippelli G; Perri P; Botti C; Vizza E; Carpino A; Pizzuti L; Latorre A; Giannarelli D; Lopez M; Di Lauro L
J Exp Clin Cancer Res; 2011 Apr; 30(1):39. PubMed ID: 21481280
[TBL] [Abstract][Full Text] [Related]
16. Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer. A multicenter phase II trial.
Potamianou A; Androulakis N; Papakotoulas P; Toufexi H; Latoufis C; Kouroussis C; Christofilakis C; Xenidis N; Georgoulias V; Polyzos A
Oncology; 2005; 69(4):348-53. PubMed ID: 16293974
[TBL] [Abstract][Full Text] [Related]
17. Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study.
Runnebaum IB; Reichert D; Ringsdorf U; Kuther M; Hesse T; Sehouli J; Wimberger P
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1185-1195. PubMed ID: 29623421
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin and vinorelbine followed by ifosfamide plus epirubicin vs the opposite sequence in advanced unresectable stage III and metastatic stage IV non-small-cell lung cancer: a prospective randomized study of the Southern Italy Oncology Group (GOIM).
Colucci G; Gebbia V; Galetta D; Riccardi F; Cariello S; Gebbia N
Br J Cancer; 1997; 76(11):1509-17. PubMed ID: 9400950
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of liposomal doxorubicin in recurrent epithelial ovarian carcinoma.
Arcuri C; Sorio R; Tognon G; Gambino A; Scalone S; Lucenti A; Caffo O; Valduga F; Arisi E; Galligioni E
Tumori; 2004; 90(6):556-61. PubMed ID: 15762356
[TBL] [Abstract][Full Text] [Related]
20. Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.
Ichikawa R; Torii Y; Oe S; Kawamura K; Kato R; Hasegawa K; Udagawa Y
Arch Gynecol Obstet; 2014 Nov; 290(5):979-84. PubMed ID: 24798935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
